Literature DB >> 23877020

Comparison of osteoprotegerin and vascular endothelial growth factor in normoalbuminuric Type 1 diabetic and control subjects.

A Esteghamati1, A Arefzadeh, A Zandieh, M Salehi Sadaghiani, S Noshad, M Nakhjavani.   

Abstract

BACKGROUND: The aim of the current study was to evaluate the association of osteoprotegerin and vascular endothelial growth factor (VEGF) with glycemic indices and diabetes status.
METHODS: A total of 44 normoalbuminuric Type 1 diabetic patients and 44 healthy control subjects, matched for age, body mass index, sex ratio, and lipid measures were enrolled. Univariate and multivariate logistic regression analyses were used to determine the association of osteoprotegerin and VEGF with diabetes status. Further, linear regression analysis was performed to investigate the roles of osteoprotegerin and VEGF as determinants of glycated hemoglobin (HbA1c).
RESULTS: Osteoprotegerin and VEGF were significantly elevated in diabetic subjects (2.76±0.85 vs 2.26±0.75 pmol/l and 187.1±92.7 vs 125.9±52.3 pg/ml, respectively, p<0.01) and were positively correlated with glycemic indices (i.e. fasting plasma glucose and HbA1c, p<0.001). After controlling for possible confounding factors, odds ratios (confidence interval) of osteoprotegerin and VEGF for diabetes were 2.532 (1.003-6.392) and 1.021 (1.002-1.041), respectively (p<0.05). Further, linear regression analysis revealed that the association of osteoprotegerin with HbA1c is independent of VEGF and vice versa (p<0.001).
CONCLUSION: Osteoprotegerin and VEGF are elevated in normoalbuminuric Type 1 diabetic subjects and are independently associated with glycemic indices and diabetes status.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23877020     DOI: 10.1007/bf03347110

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  30 in total

Review 1.  Vascular endothelial growth factor (VEGF) - part 1: in physiology and pathophysiology.

Authors:  Dariusz Kajdaniuk; Bogdan Marek; Halina Borgiel-Marek; Beata Kos-Kudła
Journal:  Endokrynol Pol       Date:  2011       Impact factor: 1.582

2.  Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women.

Authors:  W S Browner; L Y Lui; S R Cummings
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

3.  Comparison of osteoprotegerin to traditional atherosclerotic risk factors and high-sensitivity C-reactive protein for diagnosis of atherosclerosis.

Authors:  Rasmus Mogelvang; Sune H Pedersen; Allan Flyvbjerg; Mette Bjerre; Allan Z Iversen; Soren Galatius; Jan Frystyk; Jan S Jensen
Journal:  Am J Cardiol       Date:  2011-11-17       Impact factor: 2.778

4.  Albuminuria and VEGF as early markers of cardiovascular disturbances in young type 1 diabetic patients.

Authors:  Dariusz Naskret; Dorota A Zozulinska-Ziolkiewicz; Rafal Dankowski; Henryk Wysocki; Bogna Wierusz-Wysocka
Journal:  Microvasc Res       Date:  2010-07-24       Impact factor: 3.514

5.  Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha.

Authors:  P Olesen; T Ledet; L M Rasmussen
Journal:  Diabetologia       Date:  2005-02-08       Impact factor: 10.122

6.  Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease.

Authors:  Shuichi Jono; Yuji Ikari; Atsushi Shioi; Katsuhito Mori; Takami Miki; Kazuhiro Hara; Yoshiki Nishizawa
Journal:  Circulation       Date:  2002-09-03       Impact factor: 29.690

7.  Osteoprotegerin and mortality in type 2 diabetic patients.

Authors:  Henrik Reinhard; Maria Lajer; Mari-Anne Gall; Lise Tarnow; Hans-Henrik Parving; Lars M Rasmussen; Peter Rossing
Journal:  Diabetes Care       Date:  2010-10-07       Impact factor: 19.112

8.  Increased plasma osteoprotegerin concentrations in Type 1 diabetes with albuminuria.

Authors:  Shen-tian Wang; Jian-min Xu; Meng Wang; Fu-lian Chen; Gang Ding
Journal:  Clin Nephrol       Date:  2013-03       Impact factor: 0.975

9.  Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-alpha levels in men with type 2 diabetes.

Authors:  Subhashini Yaturu; Justin Rains; Sushil K Jain
Journal:  Cytokine       Date:  2008-09-11       Impact factor: 3.861

Review 10.  Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?

Authors:  B G Nordestgaard; J Zacho
Journal:  Nutr Metab Cardiovasc Dis       Date:  2009-08-19       Impact factor: 4.222

View more
  1 in total

Review 1.  Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment.

Authors:  Nur Samsu
Journal:  Biomed Res Int       Date:  2021-07-08       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.